Introduction
============

Chronic kidney disease (CKD) is an irreversible and progressive disease that is characterised by kidney damage and renal function decline. In a clinical setting, the renal function in CKD patients is measured in estimated glomerular filtration rate (eGFR) ([@ref-25]). Most CKD cases are caused by type 2 diabetes which is characterised by long-term hyperglycaemia attributed to insulin resistance and insulin insufficiency. Hyperglycaemia increases the risk of many diabetic complications, including diabetic kidney disease ([@ref-2]).

CKD is associated with enhanced oxidative stress that is triggered when the antioxidants are unable to counteract the harmful oxidative insults caused by excessive production of reactive oxygen species. The enzymatic antioxidants such as superoxide dismutase (SOD) and glutathione peroxidase (GPx) form a part of the antioxidant defense against oxidative insults. Superoxide anion, a highly reactive ROS, is converted by superoxide dismutase SOD to hydrogen peroxide, which is then reduced to water by catalase and GPx ([@ref-13]). The activities of enzymatic antioxidants are generally decreased in diabetic patients with CKD ([@ref-40]) and antioxidant therapy has been shown to lower the risk of albuminuria in diabetic patients ([@ref-3]).

Receptor for advanced glycation end-products (RAGE) is a type of cell surface receptor of immunoglobulin superfamily that binds to an array of ligands, including advanced glycation end-products (AGEs) ([@ref-31]). AGEs represent a heterogeneous group of molecules, including pentosidine and Nepsilon-(carboxymethyl)lysine, that are produced as a result of glycation of proteins, lipids or nucleic acids by reducing sugars ([@ref-14]). Soluble form of RAGE (sRAGE) is the most commonly described variant of RAGE which circulates in the blood. Ligand-binding to sRAGE circumvents the deleterious events such as oxidative stress, inflammation and apoptosis arising from the RAGE-ligand binding ([@ref-16]). In fact, sRAGE also shows nephroprotective effects such as improvements in albuminuria and renal function in diabetic nephropathy ([@ref-38]).

Haemoglobin A1c (HbA1c) is commonly used as a tool for monitoring diabetes and hyperglycaemia. HbA1c is a form of glycated haemoglobin which is an indicator of average plasma glucose concentration over three months ([@ref-35]). Controlling diabetes and hyperglycaemia has beneficial effects against kidney disease. Long-term intensive glycaemic control has been shown to reduce the risk of kidney failure ([@ref-41]). Besides, tight glycaemic control could also lessen the risks of myocardial infarction, onset and progression of albuminuria in diabetic kidney disease ([@ref-33]).

Despite the favourable outcomes of well-controlled diabetes, the effect of glycaemic control on enzymatic antioxidants and sRAGE in diabetic CKD patients is hitherto unknown. Therefore, the aim of this study was to investigate the impact of glycaemic control status on the activities or levels of GPx, SOD and sRAGE in CKD patients. The present study sheds light on whether poor glycaemic control is associated with diminished activities of enzymatic antioxidants and increased sRAGE levels in diabetic CKD.

Materials & Methods
===================

Recruitment of study participants
---------------------------------

The study participants selected in this study were a subset of those recruited earlier as described in a published report ([@ref-40]). In the present study, CKD patients were recruited from University Malaya Medical Centre (UMMC), Kuala Lumpur. The CKD patients whose eGFR have been constantly less than 60 ml/min/1.73 m^2^ for at least six months before recruitment. Kidney transplant recipients and patients with acute kidney injury were not enrolled into this study. A total of 150 CKD patients were categorised into diabetic CKD (D-CKD) patients and non-diabetic CKD (ND-CKD) patients. The D-CKD patients (*n* = 116) were diagnosed with type 2 diabetes while the ND-CKD patients (*n* = 34) were those with hypertension (16), chronic glomerulonephritis (nine), obstructive uropathy (three), analgesic nephropathy (two), polycystic kidney disease (two) and IgA nephropathy (two). The D-CKD patients were divided into subgroups based on their HbA1c levels, namely poor glycaemic control (GC) and good GC. The D-CKD patients with poor GC (*n* = 63) had HbA1c \> 7% while the D-CKD patients with good GC (*n* = 53) had HbA1c ≤7% ([@ref-15]).

The non-CKD patients who served as controls in this study were also recruited from UMMC. A total of 64 non-CKD patients whose eGFR have been consistent and higher than 60 ml/min/1.73 m^2^ were selected. These non-CKD patients were classified into diabetic (DM) patients (*n* = 46) who had type 2 diabetes, and non-diabetic (non-DM) patients (*n* = 18) who were afflicted with other chronic diseases such as cardiovascular disease, hypertension, neurodegenerative diseases and osteoporosis. The DM patients were also further divided into patients with poor GC (*n* = 26) and good GC (*n* = 20).

Peripheral venous blood of the study participants was collected in EDTA tubes. Plasma was isolated immediately after blood collection through centrifugation for 10 min at 2,000× g. The plasma specimens were kept at −80 °C prior to the quantitation of GPx, SOD and sRAGE. Extra blood specimens were also collected for routine blood tests required for clinical examination of the patients.

This study was approved by the Medical Ethics Committee UMMC with adherence to the Declaration of Helsinki (Ethics Committee/IRB reference number: 982.17). Both verbal and written informed consent were obtained prior to blood collection.

Routine blood tests
-------------------

The blood tests were performed using standard laboratory procedures in the Division of Laboratory Medicine, UMMC. The levels or activities of serum creatinine, alanine transaminase (ALT), aspartate aminotransferase (AST), triglycerides, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol and fasting glucose were measured in an ADVIA^®^ 2400 Clinical Chemistry System (Siemens Healthcare Diagnostics, Erlangen, Germany). Sodium lauryl sulfate method was used to measure hemoglobin concentration in a XE-5000 Automated Hematology Analyzer (Sysmex Corporation, Kobe, Japan). Ion-exchange high-performance liquid chromatography assay was used for the measurement of glycated haemoglobin (HbA1c) in VARIANT™ II TURBO Hemoglobin Testing System (Bio-Rad, Hercules, CA, USA). Modified 4-variable Modification of Diet in Renal Disease study equation ([@ref-26]) was used to calculate the eGFR of the study participants.

Assays of enzymatic antioxidants
--------------------------------

Both Glutathione Peroxidase Assay Kit and Superoxide Dismutase Assay Kit (Cayman Chemical, Ann Arbor, MI, USA) were used to measure the antioxidant activities of plasma glutathione peroxidase (GPx) and plasma superoxide dismutase (SOD) respectively. The measurements were carried out according to the manufacturer's protocols. The absorbance was measured in a microtiter-plate ELISA reader, Power Wave X 340 (Bio-Tek Instruments Inc., Winooski, VT, USA).

Soluble RAGE ELISA assay
------------------------

Human RAGE Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA) was used to measure sRAGE in plasma according to the manufacturer's protocol. This ELISA kit applies the quantitative sandwich enzyme immunoassay technique to target and bind the extracellular domain of the human sRAGE proteins. The absorbance was measured in a Power Wave X 340 microtiter-plate reader (Bio-Tek Instruments Inc., Winooski, VT, USA).

Statistical tests
-----------------

The statistical analyses were performed using the Statistical Package for Social Sciences, version 20 (SPSS Inc., Chicago, IL, USA). The significance threshold was set at *P* \< 0.05. The normality of data distribution was examined using Shapiro--Wilk test. For dependent variables of non-normal distribution, Kruskal--Wallis test was performed to examine overall differences in medians between two or more groups of study participants. If the differences in medians were proved to be significant, pairwise comparisons between two participant groups were conducted using Mann--Whitney *U* test. The differences in categorical variables between participant groups were analysed using Chi-squared test.

Two-way analysis of variance (ANOVA) was used to analyse the interaction of CKD status (CKD and non-CKD) and glycaemic control status (poor GC and good GC) on GPx, SOD and sRAGE in diabetic subjects (D-CKD and DM patients). Pairwise comparisons were not conducted following significant main effect of CKD status or glycaemic control status because each of them consists of only two levels. Follow-up analyses were performed if the interaction effect between CKD status and glycaemic control status was significant. Simple main effect test was conducted to evaluate the differences in means of dependent variable between CKD patients and non-CKD patients for each glycaemic control status, as well as between poor GC and good GC for each CKD status. Interaction analysis was performed to evaluate whether the difference in means between CKD patients and non-CKD patients of poor GC were equal to the difference in means between CKD patients and non-CKD patients of good GC. A significant interaction reflects that the differences are not equal to each other. Bonferroni approach was used to set corrected significance threshold (*P*~corr~) to control for Type I error in this analysis.

Results
=======

Characteristics of study participants
-------------------------------------

The baseline characteristics of CKD and non-CKD patients are listed in [Table 1](#table-1){ref-type="table"}. Both D-CKD patients and ND-CKD patients showed significantly higher serum creatinine and lower eGFR as compared with DM patients (*P* \< 0.001) and non-DM patient (*P* \< 0.001), indicating reduced renal function among the CKD patients. The HbA1c levels and fasting glucose levels were higher in D-CKD patients and DM patients than in the ND-CKD patients (*P* \< 0.001) and non-DM patients (*P* \< 0.001). The fasting glucose levels were slightly lower in ND-CKD patients than in the non-DM patients (*P* \< 0.01). There were less biguanide users (*P* \< 0.001) but more insulin users (*P* \< 0.001) in D-CKD patients than in the DM patients. The usage of ACEI and ARB in non-DM patient group was less than in DM patient group (*P* \< 0.05) and ND-CKD patient group (*P* \< 0.05). Furthermore, more DM patients were using statins as compared to non-DM patients (*P* \< 0.05).
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###### Baseline characteristics of CKD and non-CKD patients.

![](peerj-06-4421-g001)

                                                     CKD                                                               Non-CKD                                                                                                         
  -------------------------------------------------- ----------------------------------------------------------------- --------------------------------------------------------- ----------------------------------------------------- ----------------------------
  Age (years)                                        66.0 (45.0 to 75.0)                                               64.0 (41.0 to 74.0)                                       64.0 (45.0 to 75.0)                                   64.0 (53.0 to 73.0)
  Gender (male (%)/female (%))                       78 (67.2)/38 (32.8)                                               22 (64.7)/12 (35.3)[^c1^](#table-1fn7){ref-type="fn"}     24 (52.2)/22 (47.8)                                   6 (33.3)/12 (66.7)
  Ethnic groups (Malay (%)/Chinese (%)/Indian (%))   51 (44.0)/40 (34.5)/25 (21.5)[^b2^](#table-1fn5){ref-type="fn"}   14 (41.2)/15 (44.1)/5 (14.7)                              8 (17.4)/20 (43.5)/18 (39.1)                          6 (33.3)/8 (44.5)/4 (22.2)
  Urea (mmol/l)                                      11.3 (3.9 to 34.0)[^b3^](#table-1fn6){ref-type="fn"}              11.1 (3.7 to 27.0)[^c3^](#table-1fn9){ref-type="fn"}      4.6 (1.7 to 10.7)                                     4.5 (2.1 to 9.7)
  Serum creatinine (µmol/l)                          191.0 (103.0 to 567.0)[^b3^](#table-1fn6){ref-type="fn"}          189.5 (86.0 to 481.0)[^c3^](#table-1fn9){ref-type="fn"}   70.5 (40.0 to 106.0)                                  61.5 (43.0 to 92.0)
  eGFR (ml/min/1.73 m^2^)                            28.6 (4.2 to 53.3)[^b3^](#table-1fn6){ref-type="fn"}              31.0 (9.0 to 58.0)[^c3^](#table-1fn9){ref-type="fn"}      82.3 (65.5 to 146.6)                                  91.0 (73.08 to 127.04)
  CKD stage 3 (%)/4 (%)/5 (%)                        56 (48.3)/49 (42.2)/11 (9.5)                                      18 (52.9)/12 (35.3)/4 (11.8)                              N/A                                                   N/A
  ALT (U/l)                                          23.0 (8.0 to 90.0)                                                26.5 (6.0 to 90.0)                                        28.0 (10.0 to 79.0)                                   28.0 (14.0 to 55.0)
  AST(U/l)                                           22.0 (12.0 to 88.0)                                               22.0 (7.0 to 80.0)                                        23.0 (13.0 to 61.0)                                   25.0 (18.0 to 38.0)
  Triglyceride (mmol/l)                              1.7 (0.5 to 5.2)[^b1^](#table-1fn4){ref-type="fn"}                1.7 (0.8 to 5.5)                                          1.4 (0.5 to 4.2)                                      1.3 (0.6 to 3.2)
  Total cholesterol (mmol/l)                         4.4 (2.3 to 9.9)                                                  4.5 (3.3 to 18.1)                                         4.5 (3.0 to 6.9)                                      5.0 (3.2 to 7.1)
  HDL-cholesterol (mmol/l)                           1.0 (0.1 to 3.2)[^b1^](#table-1fn4){ref-type="fn"}                1.2 (0.7 to 2.5)                                          1.3 (0.9 to 2.3)[^c1^](#table-1fn7){ref-type="fn"}    1.4 (1.0 to 2.5)
  LDL-cholesterol (mmol/l)                           2.3 (1.2 to 7.7)                                                  2.4 (1.4 to 15.8)                                         2.4 (1.1 to 4.5)                                      2.8 (1.7 to 5.0)
  Haemoglobin (g/l)                                  118.0 (76 to 165.0)[^b1^](#table-1fn4){ref-type="fn"}             122.0 (98.0 to 155.0)[^c1^](#table-1fn7){ref-type="fn"}   122.0 (113.0 to 148.0)                                135.5 (99.0 to 158.0)
  HbA1c (%)                                          7.4 (3.8 to 13.7)[^a^](#table-1fn3){ref-type="fn"}                5.6 (4.4 to 7.0)                                          7.3 (5.1 to 13.2)[^c3^](#table-1fn9){ref-type="fn"}   5.7 (4.7 to 6.5)
  Fasting glucose (mmol/l)                           7.4 (2.9 to 17.8)[^a^](#table-1fn3){ref-type="fn"}                5.1 (3.9 to 6.0)[^c2^](#table-1fn8){ref-type="fn"}        7.4 (3.2 to 21.1)[^c3^](#table-1fn9){ref-type="fn"}   5.5 (4.6 to 6.7)
  Use of medications (%)                                                                                                                                                                                                               
  Sulfonylureas                                      48.7                                                              N/A                                                       46.5                                                  N/A
  Biguanides                                         23.4[^b3^](#table-1fn6){ref-type="fn"}                            N/A                                                       86.1                                                  N/A
  Insulin                                            50.5[^b3^](#table-1fn6){ref-type="fn"}                            N/A                                                       18.6                                                  N/A
  ACEI                                               42.3                                                              37.5                                                      48.8[^c1^](#table-1fn7){ref-type="fn"}                17.7
  ARB                                                41.4                                                              41.7[^c1^](#table-1fn7){ref-type="fn"}                    25.6                                                  11.8
  Statins                                            91.9                                                              79.2                                                      88.4[^c1^](#table-1fn7){ref-type="fn"}                64.7
  GPx (nmol/min/ml)                                  94.2 (50.1 to 180.0)[^b2^](#table-1fn5){ref-type="fn"}            97.6 (50.1 to 154.5)                                      107.9 (47.5 to 145.2)                                 110.8 (75.6 to 155.4)
  SOD (U/ml)                                         16.6 (2.3 to 76.1)[^b3^](#table-1fn6){ref-type="fn"}              16.6 (8.3 to 37.7)[^c2^](#table-1fn8){ref-type="fn"}      28.5 (12.8 to 96.5)                                   26.0 (15.5 to 87.2)
  sRAGE (pg/ml)                                      1,097.0 (224.8 to 6,438.0)[^b3^](#table-1fn6){ref-type="fn"}      870.9 (157.9 to 2,296.0)                                  564.8 (249.9 to 1,702.0)                              667.6 (297.9 to 1,115.0)

**Notes.**

Data are expressed as median (range). Categorical variables are expressed as either numbers or percentages.

D-CKDdiabetic CKD patientsND-CKDnon-diabetic CKD patientsDMdiabetic patients withoutCKD, Non-DMnon-diabetic patients without CKDN/Anot available

*P* \< 0.001 versus ND-CKD.

*P* \< 0.05,

*P* \< 0.01,

*P* \< 0.001 versus DM.

*P* \< 0.05,

*P* \< 0.01,

*P* \< 0.001 versus Non-DM.

The D-CKD patients showed significantly lower medians of plasma GPx activity (*P* \< 0.01) and SOD activity (*P* \< 0.001) than DM patients. The ND-CKD patients also exhibited decreased median of SOD activity in comparison to non-DM patients (*P* \< 0.01). In addition, the median of plasma sRAGE level was significantly elevated in D-CKD patients than in DM patients (*P* \< 0.001).
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###### Renal markers, enzymatic antioxidants and sRAGE in study participants upon stratification of glycaemic control status.

![](peerj-06-4421-g002)

  Parameters                  Overall significance of difference in medians   CKD patients      Non-CKD patients                                                                                                                                                                                                                                                                                                                           
  --------------------------- ----------------------------------------------- ----------------- ------------------------------------------------------------- -------------------------------------------------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- --------------------------
  Urea (mmol/l)               112.37                                          \<0.001           10.1 (3.9 to 24.9)[^b^](#table-2fn4){ref-type="fn"}           12.7 (3.9 to 34.0)[^c2^](#table-2fn6){ref-type="fn"}                                               11.1 (3.7 to 27.0)[^d3^](#table-2fn9){ref-type="fn"}      4.5 (2.6 to 10.7)                                       4.7 (1.7 to 6.5)                                        4.5 (2.1 to 9.7)
  Serum creatinine (µmol/l)   133.77                                          \<0.001           185.0 (103.0 to 363.0)[^b^](#table-2fn4){ref-type="fn"}       211.5 (117.0 to 567.0)[^c2^](#table-2fn6){ref-type="fn"}                                           189.5 (86.0 to 481.0)[^d3^](#table-2fn9){ref-type="fn"}   69.5 (40.0 to 98.0)                                     74.5 (42.0 to 106.0)                                    61.5 (43.0 to 92.0)
  eGFR (ml/min/1.73m^2^)      136.03                                          \<0.001           30.9 (10.9 to 49.6)[^b^](#table-2fn4){ref-type="fn"}          25.2 (4.2 to 53.3)[^c2^](#table-2fn6){ref-type="fn"}                                               31.0 (9.0 to 58.4)[^d3^](#table-2fn9){ref-type="fn"}      86.3 (67.6 to 146.6)                                    78.9 (65.5 to 132.2)                                    91.0 (73.1 to 127.0)
  GPx (nmol/min/ml)           10.64                                           Not significant   94.2 (50.1 to 180.0)                                          94.2 (57.7 to 177.4)                                                                               97.6 (50.1 to 154.5)                                      110.0 (70.5 to 145.2)                                   103.6 (47.5 to 141.8)                                   110.8 (75.6 to 155.4)
  SOD (U/ml)                  54.34                                           \<0.001           17.1 (2.3 to 76.1)[^b^](#table-2fn4){ref-type="fn"}           15.9 (8.1 to 64.7)[^c2^](#table-2fn6){ref-type="fn"}                                               16.6 (8.3 to 37.7)[^d2^](#table-2fn8){ref-type="fn"}      24.4 (12.8 to 96.5)[^c2^](#table-2fn6){ref-type="fn"}   35.7 (22.2 to 75.7)[^d1^](#table-2fn7){ref-type="fn"}   26.0 (15.5 to 87.2)
  sRAGE (pg/ml)               37.61                                           \<0.001           1,086.0 (237.4 to 5,817.0)[^b^](#table-2fn4){ref-type="fn"}   1,113.0 (224.8 to 6,438.0)[^a^](#table-2fn3){ref-type="fn"}^,^[^c2^](#table-2fn6){ref-type="fn"}   870.9 (157.9 to 2,296.0)                                  569.0 (249.9 to 1,702.0)                                536.9 (323.1 to 1,321.0)                                667.6 (297.9 to 1,115.0)

**Notes.**

Data are expressed as median (range).

*χ*^2^Chi-squared value*PP*-valueD-CKDdiabetic CKD patientsND-CKDnon-diabetic CKD patientsDMdiabetic patients withoutCKDNon-DM, non-diabetic patients without CKDPGCpoor glycaemic control with HbA1c \>7%GGCgood glycaemic control with HbA1c ≤7%eGFRestimated glomerular filtration rateGPxglutathione peroxidaseSODsuperoxide dismutasesRAGEsoluble RAGE

*P* \< 0.05 versus ND-CKD.

*P* \< 0.001 versus DM (PGC).

*P* \< 0.01,

*P* \< 0.001 versus DM (GGC).

*P* \< 0.05,

*P* \< 0.01,

*P* \< 0.001 versus Non-DM.

Renal markers, enzymatic antioxidants and sRAGE in study participants upon stratification of glycaemic control status
---------------------------------------------------------------------------------------------------------------------

The medians of urea, serum creatinine, eGFR, GPx, SOD and sRAGE were compared between groups of study participants in non-parametric Kruskal--Wallis test. Pairwise comparisons using Mann--Whitney *U* test were performed for each parameter that showed overall significance of median difference in Kruskall--Wallis test, except for GPx ([Table 2](#table-2){ref-type="table"}).

D-CKD patients with poor GC, D-CKD patients with good GC and ND-CKD patients showed significantly higher levels of urea and serum creatinine, and lower levels of eGFR than their non-CKD counterparts (*P* \< 0.001). No significant differences in these renal markers were observed between study participants of different diabetes status and glycaemic control status in CKD patients, as well as in non-CKD patients.

In general, no significant differences in GPx medians between participant groups were detected. The present study showed no significant differences in plasma SOD activities between D-CKD patients and ND-CKD patients, regardless of their glycaemic control status. The SOD activities were significantly reduced in the CKD patients than in the non-CKD patients. The D-CKD patients with poor GC, D-CKD patients with good GC and ND-CKD patients exhibited significantly lower SOD activities compared to DM patients with poor GC (*P* \< 0.001), D-CKD patients with good GC (*P* \< 0.001) and non-DM patients (*P* \< 0.01) respectively. In this study, SOD was the only parameter that showed statistically significant differences among non-CKD patient groups. The SOD activities in DM patients with good GC was significantly higher than the DM patients with poor GC ( *P* \< 0.001) and non-DM patients (*P* \< 0.05). On the other hand, the D-CKD patients with good GC exhibited higher plasma sRAGE levels than ND-CKD patients (*P* \< 0.05). In addition, sRAGE levels were significantly higher in D-CKD patients with poor GC and good GC than in the DM patients with poor GC (*P* \< 0.001) and good GC (*P* \< 0.001) respectively.

Interaction between CKD status and glycaemic control status on GPx, SOD and sRAGE
---------------------------------------------------------------------------------

[Table 3](#table-3){ref-type="table"} shows the means and standard deviations for GPx, SOD and sRAGE in diabetic subjects. Two-way ANOVA was conducted to analyse the interaction effects of two factors --CKD status and glycaemic control status on GPx, SOD and sRAGE in diabetic subjects (D-CKD and DM patients) ([Table 4](#table-4){ref-type="table"}). Both CKD status and glycaemic control status showed significant interaction effect on SOD (*P* \< 0.01), in addition to the separate, significant main effect of each factor. There were no significant interaction effects on GPx and sRAGE. Nonetheless, CKD status showed significant main effect on GPx (*P* \< 0.05) and sRAGE (*P* \< 0.001) in this group of study participants. The results showed that the means of these parameters were significantly different between CKD patients and non-CKD patients, whereas no significant differences were detected between diabetic subjects with poor GC and good GC. Follow-up tests for SOD such as simple main effect test and interaction comparison were performed following the significant interaction effect.
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###### Means and standard deviations for GPx, SOD and sRAGE in diabetic subjects.
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  Parameter   Glycaemic control status   CKD status                     
  ----------- -------------------------- ------------ --------- ------- -------
  GPx         Poor GC                    93.8         27.0      105.4   20.4
              Good GC                    96.0         27.8      104.2   26.1
  SOD         Poor GC                    21.0         12.8      28.3    15.4
              Good GC                    20.2         10.6      39.7    15.4
  sRAGE       Poor GC                    1,326.6      902.3     707.4   386.0
              Good GC                    1,657.3      1,407.2   687.0   286.5

**Notes.**

GCglycaemic controlGPxglutathione peroxidaseSODsuperoxide dismutasesRAGEsoluble RAGE

10.7717/peerj.4421/table-4

###### Analysis of interaction between CKD status and glycaemic control status in study participants with diabetes.
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  Parameters          Factors                                                       *F*     *P*
  ------------------- ------------------------------------------------------------- ------- -----------------
  GPx (nmol/min/ml)   CKD status                                                    4.64    \<0.05
                      Glycaemic control status                                      0.01    Not significant
                      Interaction between CKD status and glycaemic control status   0.14    Not significant
  SOD (U/ml)          CKD status                                                    35.13   \<0.001
                      Glycaemic control status                                      5.47    \<0.05
                      Interaction between CKD status and glycaemic control status   7.22    \<0.01
  sRAGE (pg/ml)       CKD status                                                    20.41   \<0.001
                      Glycaemic control status                                      0.78    Not significant
                      Interaction between CKD status and glycaemic control status   1.00    Not significant

**Notes.**

*F*F statistic*PP*-valuepartial *η*^2^partial eta squared valueGPxglutathione peroxidaseSODsuperoxide dismutasesRAGEsoluble RAGE
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###### Simple main effect test of SOD activities between CKD patients and non-CKD patients for each glycaemic control status.
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  Glycaemic control status   Mean difference of plasma SOD activities between CKD patients and non-CKD patients   95% confidence interval for the mean difference   Standard error   *P*   
  -------------------------- ------------------------------------------------------------------------------------ ------------------------------------------------- ---------------- ----- -------------------------------------------
  Poor GC                    −7.3                                                                                 −13.3                                             −1.4             3.0   0.016[^\*^](#table-5fn2){ref-type="fn"}
  Good GC                    −19.5                                                                                −26.2                                             −12.8            3.4   \<0.001[^\*^](#table-5fn2){ref-type="fn"}

**Notes.**

GCglycaemic controlSODsuperoxide dismutase*PP*-value

The difference is significant at *P*~corr~ \<0.025 upon Bonferroni correction.
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###### Simple main effect test of SOD activities between poor GC and good GC for each CKD status.
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  CKD status   Mean difference of plasma SOD activities between poor GC and good GC   95% confidence interval for the mean difference   Standard error   *P*   
  ------------ ---------------------------------------------------------------------- ------------------------------------------------- ---------------- ----- -----------------------------------------
  CKD          0.88                                                                   −4.0                                              5.5              2.4   0.743
  Non-CKD      −11.4                                                                  −19.0                                             −3.8             3.8   0.003[^\*^](#table-6fn2){ref-type="fn"}

**Notes.**

GCglycaemic controlSODsuperoxide dismutase*PP*-value

The difference is significant at *P*~corr~ \< 0.025 upon Bonferroni correction.

The significance threshold was set at 0.025 for each of the two simple main effects to control for Type I error ([Tables 5](#table-5){ref-type="table"} and [6](#table-6){ref-type="table"}). The differences in SOD means were separately examined in simple main effect tests. The SOD activities were significantly lower in CKD patients than in the non-CKD patients for each glycaemic control status (*P*~corr~ \< 0.025) ([Table 5](#table-5){ref-type="table"}). However, another simple main effect test ([Table 6](#table-6){ref-type="table"}) showed that the SOD activities were only significantly lower in non-CKD patients with poor GC than in those with good GC (*P*~corr~ \< 0.025) whereas such comparison did not show significant difference in CKD patients. These results pointed out that the non-CKD patients with good GC was associated with higher SOD activities, whereas the SOD activities among the CKD patients with poor GC and good GC were comparable.

Interaction comparison was conducted to address whether the absence of CKD and good GC in diabetic subjects are associated with high SOD activities ([Table 7](#table-7){ref-type="table"}). The contrast estimate of 12.2 represents the difference in SOD means between CKD and non-CKD for poor GC minus the difference in SOD means between CKD and non-CKD for good GC (*P* \< 0.01). The results of this comparison supported that the non-CKD patients with good GC would benefit from higher SOD activities as compared with other groups of study participants.

10.7717/peerj.4421/table-7

###### Interaction comparison between CKD and non-CKD for poor GC versus good GC.

![](peerj-06-4421-g007)

  ------------------------- -------------
  Contrast estimate         12.2
  95% confidence interval   3.2 to 21.1
  *F*                       7.22
  *P*                       \<0.01
  ------------------------- -------------

**Notes.**

GCglycaemic control*F*statistic*PP*-value

The results of interaction analysis between CKD status and diabetes status in all of the study participants were presented in Supporting Information files ([Tables S1](#supp-2){ref-type="supplementary-material"} and [S2](#supp-2){ref-type="supplementary-material"}). The means of GPx, SOD and sRAGE were significantly different between CKD and non-CKD individuals. On the other hand, there were no significant differences in the means of these parameters between diabetic and non-diabetic individuals.

Discussion
==========

Enzymatic antioxidants and sRAGE have central roles in counteracting oxidative stress and ameliorating pathological features in diabetic nephropathy. The SOD and sRAGE have been shown to alleviate fibrosis and albuminuria as well as improve renal function in rats with diabetic nephropathy ([@ref-38]; [@ref-22]). Maintaining the blood glucose level within the normal range can decrease the risk of albuminuria, which is a risk factor for renal progression ([@ref-33]). Recent study also showed that higher HbA1c levels were associated with increased cardiovascular mortality in diabetic kidney disease patients ([@ref-6]).

In general, the present study showed that activities of enzymatic antioxidants and sRAGE levels were comparable among diabetic CKD patients with poor and good glycaemic control. This suggests that the levels of glycaemic control do not account for the quantitative alterations in GPx, SOD and sRAGE in diabetic CKD patients. Regardless of glycaemic control status, diabetic CKD patients manifested diminished SOD activities and increased sRAGE levels. Thus, the presence of CKD is an important factor that explains such changes of SOD and sRAGE in diabetic patients whereas the different levels of glycaemic control do not affect these parameters in diabetic CKD patients. According to these findings, the presence of CKD may override the effect of glycaemic control in altering the enzymatic antioxidant activities and sRAGE levels.

In this study, CKD patients manifested lower plasma SOD activity than non-CKD patients. This indicates that the patients with renal dysfunction are associated with enhanced oxidative stress. Although this is a speculation, downregulation of SOD expression and enhanced oxidative stress have been reported in murine models with chronic kidney failure that were induced by 5/6 nephrectomy ([@ref-36]; [@ref-10]). The present study showed that SOD activities were higher in patients with well-controlled diabetes. The interaction analysis corroborates the association between increased SOD activities and non-CKD patients with well-controlled diabetes. Therefore, an improvement in glycaemic control in diabetic patients could lead to an increase in SOD activities that helps counteract the increasing oxidative stress in diabetes mellitus or hyperglycaemia. Therefore, an upregulation of SOD could potentially slow down the progression of diabetic CKD in patients with well-controlled diabetes. On the other hand, the presence of CKD negates the effect of glycaemic control on the changes of SOD activities in diabetic CKD patients. This shows that renal dysfunction is associated with lower SOD activities that could not be modulated through controlling hyperglycaemia.

The present study did not show overall differences in GPx activities among the six groups. Based on the results of two-way ANOVA, the diabetic CKD patients manifested lower GPx activities than non-CKD patients, irrespective of their glycaemic control status. This supports the view that GPx activities are decreased in patients with renal dysfunction ([@ref-43]). Of note, the progression of kidney disease is associated with GPx activity decline ([@ref-11]), indicating the changes in GPx activities depend on the levels of renal function. Although poorly-controlled diabetes is associated with lower GPx activities ([@ref-19]), the comparable GPx activities among CKD patients with poor and good glycaemic control in this study points out that presence of CKD would predispose the diabetic patients to lower activities of enzymatic antioxidants.

Consistent with the current findings, renal failure has predominant contribution over type 2 diabetes towards the augmentation of oxidative stress characterised by the reduction of enzymatic antioxidant activities and the elevation of oxidative damage markers ([@ref-23]). Therefore, the presence of kidney dysfunction is the mainstay of heightened oxidative stress in type 2 diabetic patients. This is evident in type 2 diabetic patients with nephropathy whose enzymatic antioxidants such as GPx, SOD and glutathione reductase were depleted while the levels of malondialdehyde, an oxidative damage marker, were elevated ([@ref-21]). Our findings also suggest that good glycaemic control does not restore the activities of enzymatic antioxidants in diabetic CKD patients whose antioxidant capacities are commonly diminished. Well-controlled diabetes also does not contribute to an improvement in parameters such as urea, serum creatinine and eGFR in CKD patients. Nevertheless, the risk of albuminuria can be alleviated through tight glycaemic control and antioxidant treatment ([@ref-3]; [@ref-33]).

The comparable sRAGE levels in diabetic CKD patients with poor and good glycaemic control in the present study highlights that the presence of CKD negates the impact of glycaemic control on sRAGE levels. These findings concur with a review by [@ref-20] which stated that the sRAGE levels are greatly affected by the presence of CKD in type 2 diabetic patients. Although the current analyses did not show significant interaction effect between CKD and diabetes on sRAGE, it has been postulated that the increased sRAGE levels in diabetes and renal dysfunction may be caused by the increased levels of AGEs ([@ref-30]). In diabetic milieu, hyperglycaemia results in a concerted increase in RAGE expression and the levels of AGEs ([@ref-42]). The diabetes-induced reactive oxygen species and AGEs induce matrix metalloproteinase-9 which cleaves the cell--surface receptor to form sRAGE, elevating the levels of sRAGE in diabetic patients ([@ref-44]; [@ref-30]). In addition, the unsatisfactory renal function in the CKD patients may also explain elevated sRAGE levels due to reduced excretion ([@ref-18]).

The AGEs and sRAGE are mainly excreted by the healthy kidneys ([@ref-37]; [@ref-17]). Under the circumstances of diabetes and kidney disease, the formation of AGEs accelerates and more sRAGE molecules are produced to neutralise the AGEs. However, excess AGEs and sRAGE are unable to be removed due to the declining renal function. In the present study, diabetic CKD patients with poor glycaemic control manifested higher sRAGE levels. This could be attributed to limited excretion and upregulation of sRAGE to thwart the deleterious effects of AGEs. Consistent with this premise, treatment of the diabetic mice with sRAGE reduced the levels of AGEs in vasculature, but did not improve glycaemia in the mice ([@ref-29]). Chronic hyperglycaemia is associated with increased generation of AGEs and oxidative damage products and exhaustion of antioxidants ([@ref-39]; [@ref-42]). Apparently, well-controlled diabetes can lowers the production of oxidative damage products such as malondialdehyde ([@ref-8]). These findings supported that sRAGE treatment and good glycaemic control hold promise in ameliorating oxidative stress.

Antidiabetic drugs have been shown to modulate the levels of antioxidants and sRAGE. The treatment with glyburide (sulfonylurea) restored the activities of enzymatic antioxidants such as glutathione-S-transferase and glucose-6-phosphate dehydrogenase in the liver tissues of diabetic rats ([@ref-4]). The type 2 diabetic patients who were treated with metformin (biguanide) had lower malondialdehyde levels and higher total antioxidant status ([@ref-1]). A recent *in vitro* study also demonstrated that metformin could reverse the aldehyde modification-induced inhibition of SOD and upregulate its antioxidant activities in diabetic patients ([@ref-24]). Besides, metformin also prevents oxidative burst through a reduction of reactive oxygen species and the augmentation of enzymatic antioxidant activities in lipopolysaccharide-stimulated human macrophages ([@ref-5]). The sRAGE levels were raised in type 2 diabetic patients who were treated with a combination of antidiabetic medications such as gliclazide (sulfonylurea), metformin and insulin ([@ref-9]). Of note, diabetic patients may also use other medications to treat the complications or comorbidities. For instance, diabetic patients who have hypertension and kidney disease may be given perindopril (angiotensin-converting-enzyme inhibitor) that could increase sRAGE levels ([@ref-12]), while the patients with hypercholesterolaemia may be prescribed with statins that could increase the activities of enzymatic antioxidants ([@ref-7]). Therefore, it is challenging to investigate the modulatory effects of medications on antioxidants and sRAGE due to the vast range of possible combinations and confounding factors.

There are several limitations in the present study. There is a lack of age-matched healthy controls for the comparison of GPx, SOD and sRAGE. In this study, the individuals without CKD and diabetes who were age-matched with the patients were affected by other diseases such as hypertension and cardiovascular diseases. The present study did not show significant differences in these parameters between diabetic patients and non-diabetic patients. In addition, there is a lack of data on AGEs and proteinuria. The levels of AGEs increase as a result of elevated oxidative stress during the course of CKD progression ([@ref-34]). Besides, proteinuria also deteriorates with CKD progression ([@ref-32]). It is possible that AGEs and proteinuria could be modulated by glycaemic control in diabetic CKD patients. Thus, the impact of glycaemic control on AGEs and proteinuria in diabetic CKD should not be overlooked.

In this study, the glycaemic control levels were set according to the HbA1c targets indicated for general population ([@ref-15]). However, it is recommended to use HbA1c target between 7.5% and 9.0% as the desired glycaemic outcome for the older study participants ([@ref-27]). The reason for imposing less-tight glycaemic control in the older population with diabetes is to minimise the risks and hazards of hypoglycaemic episodes, depression and low body mass index ([@ref-28]).

Conclusion
==========

Glycaemic control did not account for the changes of the activities or levels of GPx, SOD and sRAGE in diabetic CKD patients. Reduced enzymatic antioxidant capacity and increased sRAGE level are the distinctive characteristics of CKD which are hard to be modulated through good glycaemic control. The presence of CKD would override the effect of glycaemic control on GPx, SOD and sRAGE, whereas the effect of glycaemic control status in determining SOD activities was only pronounced in non-CKD patients. Therefore, reduction of oxidative stress in diabetic CKD patients may be achieved through other means such as antioxidant supplementation and sRAGE therapy.
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###### Data S1

The dataset contains the information of 214 study participants including the CKD status, diabetes status, glycaemic control status, demographic characteristics, renal function measurement (eGFR), glutathione peroxidase activity, superoxide dismutase activity and soluble RAGE level.

###### 

Click here for additional data file.
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###### Supplementary information

###### 

Click here for additional data file.

Additional Information and Declarations
=======================================

The authors declare there are no competing interests.

[Foo Nian Wong](#author-1){ref-type="contrib"} conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.

[Kek Heng Chua](#author-2){ref-type="contrib"} and [Umah Rani Kuppusamy](#author-5){ref-type="contrib"} conceived and designed the experiments, contributed reagents/materials/analysis tools, authored or reviewed drafts of the paper, approved the final draft.

[Jin Ai Mary Anne Tan](#author-3){ref-type="contrib"} analyzed the data, contributed reagents/materials/analysis tools, authored or reviewed drafts of the paper, approved the final draft.

[Chew Ming Wong](#author-4){ref-type="contrib"} prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

The Medical Ethics Committee, University Malaya Medical Centre granted approval to carry out the study with adherence to the Declaration of Helsinki (Ethics Committee/IRB reference number: 982.17).

The following information was supplied regarding data availability:

The raw data has been provided as a [Supplemental Dataset](#supplemental-information){ref-type="supplementary-material"}.
